Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease
Annals of Neurology · 2024-09 · 96 (3) · 526-538
DOI: 10.1002/ana.27003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 18.06.2024. Verfasst von Carla Abdelnour und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: tau Proteins, Lewy Body Disease, Biomarkers, Alzheimer Disease. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Objective
To determine whether plasma phosphorylated‐Tau181 (pTau181) could be used as a diagnostic biomarker of concurrent Alzheimer's disease neuropathologic change (ADNC) or amyloidosis alone, as well as a prognostic, monitoring, and susceptibility/risk biomarker for clinical outcomes in Lewy body disease (LBD).
Methods
We studied 565 participants: 94 LBD with normal cognition, 83 LBD with abnormal cognition, 114 with Alzheimer's disease, and 274 cognitively normal. Plasma pTau181 levels were measured with the Lumipulse G platform. Diagnostic accuracy for concurrent ADNC and amyloidosis was assessed with Receiver Operating Characteristic curves in a subset of participants with CSF pTau181/Aβ42, and CSF Aβ42/Aβ40 or amyloid‐β PET, respectively. Linear mixed effects models were used to examine the associations between baseline and longitudinal plasma pTau181 levels and clinical outcomes.
Results
Plasma pTau181 predicted concurrent ADNC and amyloidosis in LBD with abnormal cognition with 87% and 72% accuracy, respectively. In LBD patients with abnormal cognition, higher baseline plasma pTau181 was associated with worse baseline MoCA and CDR‐SB, as well as accelerated decline in CDR‐SB. Additionally, in this group, rapid increases in plasma pTau181 over 3 years predicted a faster decline in CDR‐SB and memory. In LBD patients with normal cognition, there was no association between baseline or longitudinal plasma pTau181 levels and clinical outcomes; however, elevated pTau181 at baseline increased the risk of conversion to cognitive impairment.
Interpretation
Our findings suggest that plasma pTau181 is a promising biomarker for concurrent ADNC and amyloidosis in LBD. Furthermore, plasma pTau181 holds potential as a prognostic, monitoring, and susceptibility/risk biomarker, predicting disease progression in LBD. ANN NEUROL 2024;96:526–538
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
- Pharma Research and Early Development, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
- Department of Biomedical Data Science, School of Medicine, Department of Statistics, School of Humanities and Sciences, Stanford University, Stanford, CA, USA.
- Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
ORCID-Profile: Carla Abdelnour, Marian Shahid-Besanti, Edward N Wilson, Melanie J Plastini, Joseph R Winer, Kathleen L Poston
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- NIGMS NIH HHS
- National Alzheimer's Coordinating Center
- Michael J. Fox Foundation for Parkinson's Research
- Alzheimer's Association
- National Institute of General Medical Sciences
- National Institute on Aging
Zitieren
APA
Abdelnour, C., Young, C. B., Shahid-Besanti, M., Smith, A., Wilson, E. N., Ramos Benitez, J., Vossler, H., Plastini, M. J., Winer, J. R., Kerchner, G. A., Cholerton, B., Andreasson, K. I., Henderson, V. W., Yutsis, M., Montine, T. J., Tian, L., Mormino, E. C., & Poston, K. L. (2024). Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease. Annals of Neurology, 96(3), 526-538. https://doi.org/10.1002/ana.27003
Vancouver
Abdelnour C, Young CB, Shahid-Besanti M, Smith A, Wilson EN, Ramos Benitez J, et al. Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease. Annals of Neurology. 2024;96(3):526-538. doi:10.1002/ana.27003
BibTeX
@article{Abdelnour2024,
author = {Abdelnour, Carla and Young, Christina B and Shahid-Besanti, Marian and Smith, Alena and Wilson, Edward N and Ramos Benitez, Javier and Vossler, Hillary and Plastini, Melanie J and Winer, Joseph R and Kerchner, Geoffrey A and Cholerton, Brenna and Andreasson, Katrin I and Henderson, Victor W and Yutsis, Maya and Montine, Thomas J and Tian, Lu and Mormino, Elizabeth C and Poston, Kathleen L},
title = {Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease},
journal = {Annals of Neurology},
year = {2024},
volume = {96},
number = {3},
pages = {526--538},
doi = {10.1002/ana.27003}
}
EUVIMED